CoChat
Sign Up
Cited by 132Treatment of Major DepressionSchizophrenia research and treatmentHistorical Psychiatry and Medical Practices

The DOI matches its Crossref record; 685 of the 691 references it cites were found in a registry or an index.

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

Millan, Mark J., Goodwin, Guy M., Meyer-Lindenberg, Andreas, Ove Ögren, Sven·2015·European Neuropsychopharmacology
DOI 10.1016/j.euroneuro.2015.01.016
Open this paper in CoChat — free account

Abstract

Modern neuropsychopharmacology commenced in the 1950s with the serendipitous discovery of first-generation antipsychotics and antidepressants which were therapeutically effective yet had marked adverse effects. Today, a broader palette of safer and better-tolerated agents is available for helping people that suffer from schizophrenia, depression and other psychiatric disorders, while complementary approaches like psychotherapy also have important roles to play in their treatment, both alone and in association with medication. Nonetheless, despite considerable efforts, current management is still only partially effective, and highly-prevalent psychiatric disorders of the brain continue to represent a huge personal and socio-economic burden. The lack of success in discovering more effective pharmacotherapy has contributed, together with many other factors, to a relative disengagement by pharmaceutical firms from neuropsychiatry. Nonetheless, interest remains high, and partnerships are proliferating with academic centres which are increasingly integrating drug discovery and translational research into their traditional activities. This is, then, a time of transition and an opportune moment to thoroughly survey the field. Accordingly, the present paper, first, chronicles the discovery and development of psychotropic agents, focusing in particular on their mechanisms of action and therapeutic utility, and how problems faced were eventually overcome. Second, it discusses the lessons learned from past successes and failures, and how they are being applied to promote future progress. Third, it comprehensively surveys emerging strategies that are (1), improving our understanding of the diagnosis and classification of psychiatric disorders; (2), deepening knowledge of their underlying risk factors and pathophysiological substrates; (3), refining cellular and animal models for discovery and validation of novel therapeutic agents; (4), improving the design and outcome of clinical trials; (5), moving towards reliable biomarkers of patient subpopulations and medication efficacy and (6), promoting collaborative approaches to innovation by uniting key partners from the regulators, industry and academia to patients. Notwithstanding the challenges ahead, the many changes and ideas articulated herein provide new hope and something of a framework for progress towards the improved prevention and relief of psychiatric and other CNS disorders, an urgent mission for our Century.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2015.01.016

Cites

685 of 685 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Research works printed but not linked: 22

  1. Buck, 2014, How digital innovation and collaboration is driving a global demand for effective reporting in research funding, Drug Discov. World, 70
  2. Carroll, 2013, Gene editing re-writing genomes with targetable nucleases, Drug Discov. World, 47
  3. Comley, 2013, Outsourced kinase profiling services – adding value to in-house kinase programmes, Drug Discov. World, 26
  4. Comley, 2014, The current status of non-biopharma drug discovery, Drug Discov. World, 62
  5. Delay, 1952, Le traitement des psychoses par une méthode neurolytique dérivée d´hibernothérapie, le 4560R.P. utilisé seul en cure prolongée et continue, C.R. Congr. alién. Neur. France, 50, 497
  6. Delay, 1952, Utilisation en thérapeutique psychiatrique d׳une phénothiazine d׳action centrale élective (4560 RP), Ann. Med. Psychol., 2, 112
  7. Downs, 2012, The challenges of the changing drug discovery model, Drug Discov. World, 9
  8. Gamber, 2014, The CRISPR/Cas9 system: cutting a path for rapid generation of more translational animal models, Drug Discov. World, 37
  9. Green, 2013, The repositioning revolution: save me from extinction to find me pastures new, Drug Discov. World, 14, 22
  10. Harrison, 2011, Mobile mental health: review of the emerging field and proof of concept study, J. Ment. Health, 20, 509, 10.3109/09638237.2011.608746 · DOI · Paper page
  11. Hunter, 2014, Collaboration for innovation is the new mantra for the pharmaceutical industry, Drug Discov.World, 9
  12. Kaltenbach, 2014, Principles for winning digital health strategies, Drug Discov. World, 9
  13. Maeder, 2014, Advancing the promise of therapeutic genomic editing, Drug Discov. World, 19
  14. Olesen, 2006, Consensus document on European brain research, J. Neurol. Neurosurg. Psychiatr., 77, i1
  15. Shen, 2011, A 6-week randomized, double-blind, placebo-controlled, comparator-referenced, multicentre trial of vabicaserin in subjects with acute exacerbation of schizophrenia, Neuropsychopharmacology, 36, S106
  16. Skripka-Serry, 2013, The great neuro-pipeline brain drain (and why big pharma hasn׳t given up on CNS disorders), Drug Discov. World, 9
  17. Salinas, 2010, A hitchhiker׳s guide to the nervous system: the complex journey of viruses and toxins, Nat. Rev. Microbiol., 8, 645, 10.1038/nrmicro2395 · DOI
  18. Suhy, 2014, In it for the long haul: vector mediated therapeutics based upon DNA-directed RNA interference, Drug Discov. World, 22
  19. Svenningsson, 2010, The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation, Mol. Psychiatry, 15, 237, 10.1038/mp.2009.80 · DOI · Paper page
  20. Swinney, 2014, Opportunities for phenotypic screening in drug discovery, Drug Discov. World, 33
  21. Williams, 2013, Informatics the same old problems, just bigger, Drug Discov. World, 14, 28
  22. Zeller, 1952, Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system, J. Pharmacol., 106, 427

Cited by

Sorted by citations

See all 132

Related

See all

Metadata

Authors
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S.
Affiliations
  • Servier (France) (FR)
  • Warneford Hospital (GB)
ORCID
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2015-05
Volume
25
Issue
5
Pages
599-656
ISSN
0924-977X (ISSN-L)
DOI
10.1016/j.euroneuro.2015.01.016
OpenAlex
W2166279367
Semantic Scholar
fcbde5665a6187ecde3bf30530ee2f19baab7906
Cited by
132
References
691
Citations by year
2026: 8 · 2025: 7 · 2024: 2 · 2023: 10 · 2022: 14 · 2021: 6 · 2020: 13 · 2019: 14 · 2018: 19 · 2017: 16 · 2016: 17 · 2015: 6
FWCI
2.43
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute for Health and Care Research (NF-SI-0513-10010)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
Keywords
neuropsychopharmacology, antipsychotic drugs, antidepressants, schizophrenia, depression, mental illness, mechanism of action, risk factors, pathophysiology, animal models, cell model, clinical trial design, biomarkers, translational research, university-industry collaboration, drug development
MeSH terms
Animals, Mental Disorders, Humans, Psychopharmacology, Psychotropic Drugs, History, 20th Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review